Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives

Critical Reviews in Oncology/Hematology

Volumn 72, Issue 2, 2009, Pages 110-124

  Capurso, Gabriele ^a   Fazio, Nicola ^b   Festa, Stefano ^a   Panzuto, Francesco ^a   De Braud, Filippo ^b   Delle Fave, Gianfranco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Angiogenesis; Carcinoids; mTOR; Pancreatic endocrine tumours; Targeted therapy; Tyrosine kinase

Indexed keywords

2 METHOXYESTRADIOL; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOZYME; ATIPRIMOD; BEVACIZUMAB; CAPECITABINE; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OXALIPLATIN; PEGINTERFERON ALPHA2B; PLACEBO; PROTEIN KINASE B; RAPAMYCIN; ROFECOXIB; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APHTHOUS ULCER; ARTIFICIAL EMBOLISM; ASTHENIA; BIOLOGICAL THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER PAIN; CANCER SURGERY; CARCINOID; CHEMOEMBOLIZATION; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HEPATIC ARTERY; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULINOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; METASTASIS; MOLECULAR MECHANICS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROENDOCRINE TUMOR; NONHUMAN; OPPORTUNISTIC INFECTION; OVARY CANCER; PANCREAS CANCER; PANCREAS ISLET CELL TUMOR; PREVALENCE; PROSTATE CANCER; RASH; REVIEW; SKIN EXFOLIATION; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; CLINICAL TRIALS AS TOPIC; ENDOCRINE GLAND NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS;

EID: 71749107776     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.01.008     Document Type: Review

References (143)

1. Modlin I.M., Oberg K., Chung D.C., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9 (2008) 61-72
2. Yao J.C., Hassan M., Phan A., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumours in 35,825 cases in the United States. J Clin Oncol 26 (2008) 3063-3072
3. Yao J.C., Eisner M.P., Leary C., et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 14 (2007) 3492-3500
4. Panzuto F., Nasoni S., Falconi M., et al. Prognostic factors and survival in endocrine tumour patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12 (2005) 1083-1092
5. Bettini R., Boninsegna L., Mantovani W., et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 19 (2008) 903-908
6. Steinmüller T., Kianmanesh R., Falconi M., et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87 (2008) 47-62
7. Oberg K., Kvols L., Caplin M., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15 (2004) 966-973
8. Aparicio T., Ducreux M., Baudin E., et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37 (2001) 1014-1019
9. Panzuto F., Di Fonzo M., Iannicelli E., et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 17 (2006) 461-466
10. Fazio N., De Braud F., Delle Fave G., and Oberg K. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. Ann Oncol 18 (2007) 13-19
11. Toumpanakis C., Meyer T., and Caplin M.E. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21 (2007) 131-144
12. O'Toole D., and Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 19 (2005) 585-594
13. Kwekkeboom D.J., de Herder W.W., Kam B.L., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (2008) 2124-2130
14. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
15. Hanahan D. Heritable formation of pancreatic beta-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315 (1985) 115-122
16. Inoue M., Hager J.H., Ferrara N., Gerber H.P., and Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1 (2002) 193-202
17. Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2 (2000) 737-744
18. Parangi S., O'Reilly M., Christofori G., et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A 93 (1996) 2002-2007
19. Bergers G., Javaherian K., Lo K.M., Folkman J., and Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 (1999) 808-812
20. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "Chemo-Switch" regimen is antiangiogenic, producing objective responses and survival benefit, in a mouse model of cancer. J Clin Oncol 23 (2005) 939-952
21. Terris B., Scoazec J.Y., Rubbia L., et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32 (1998) 133-138
22. Rubbia-Brandt L., Terris B., Giostra E., Dousset B., Morel P., and Pepper M.S. Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin Cancer Res 10 (2004) 6919-6928
23. Zhang J., Jia Z., Li Q., et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109 (2007) 1478-1486
24. Couvelard A., O'Toole D., Turley H., et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92 (2005) 94-101
25. Capurso G., Lattimore S., Crnogorac-Jurcevic, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer 13 (2006) 541-558
26. Zhang J., Jia Z., Wang L., et al. Treatment with bevacizumab (BEV) upregulates expression of the transcription factor Sp1 and its downstream target genes in human carcinoid cells: Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A (MIT). J Clin Oncol 25 18S (2007) 15031
27. Yao J.C., Phan A., Hoff P.M., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26 (2008) 1316-1323
28. Kulke M.H., Stuart K., Earle C.C., et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 24 18S (2006) 4044
29. Kunz P.L., Kuo T., Kaiser H.L., et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results. J Clin Oncol 26 Suppl. (2008) 15502
30. Venook A.P., Ko A.H., Tempero M.A., et al. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 26 Suppl. (2008) 15545
31. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
32. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
33. Kulke M.H., Lenz H.J., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26 (2008) 3403-3410
34. Bello C., Deprimo S., Friece C., et al. Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. J Clin Oncol 24 18S (2006) 4045
35. Karhoff D., Sauer S., Schrader J., et al. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 85 (2007) 45-53
36. Van Gompel J., Kunnimalaiyaan M., Holen K., and Chen H. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 4 (2005) 910-917
37. Hobday T.J., Rubin J., Holen K., et al. MC044 h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol 25 18S (2007) 4504
38. Lin B., Podar K., Gupta D., et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 62 (2002) 5019-5026
39. Pavel M.E., Bartel C., Heuck F., et al. Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC). J Clin Oncol 26 Suppl. (2008) 14684
40. Anthony L., Chester M., Michael S., O'Dorisio T.M., and O'Dorisio M.S. Phase II open-label clinical trial of vatalanib (PTK/ZK) in patients with progressive neuroendocrine cancer. J Clin Oncol 26 Suppl. (2008) 14624
41. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 (1994) 4082-4085
42. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24 (2006) 401-406
43. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312 (2006) 594-607
44. Kulke M.H., Bergsland E.K., Ryan D.P., et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24 (2006) 3555-3561
45. Wulbrand U., Wied M., Zofel P., Goke B., Arnold R., and Fehmann H. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 28 (1998) 1038-1049
46. Srivastava A., Alexander J., Lomakin I., and Dayal Y. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors. Hum Pathol 32 (2001) 1184-1189
47. Fjallskog M.L., Lejonklou M.H., Oberg K.E., Eriksson B.K., and Janson E.T. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9 (2003) 1469-1473
48. Welin S., Fjallskog M.L., Saras J., Eriksson B., and Janson E.T. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 84 (2006) 42-48
49. Bazley L.A., and Gullick W.J. The epidermal growth factor receptor family. Endocr Relat Cancer 12 Suppl. 1 (2005) S17-S27
50. Papouchado B., Erickson L.A., Rohlinger A.L., et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 18 (2005) 1329-1335
51. Shah T., Hochhauser D., Frow R., Quaglia A., Dhillon A.P., and Caplin M.E. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 18 (2006) 355-360
52. Gilbert J.A., Lloyd R.V., and Ames M.M. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. N Engl J Med 353 (2005) 209-210
53. Goebel S.U., Iwamoto M., Raffeld M., et al. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 62 (2002) 3702-3710
54. Hopfner M., Sutter A.P., Gerst B., Zeitz M., and Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). BMC Cancer 4 (2004) 23
55. Hobday T.J., Holen K., Donehower R., et al. A phase II trial of gefitinib in patients with progressive metastatic neuroendocrine tumors: a Phase II Consortium study. J Clin Oncol 24 18S (2006) 4043
56. Fletcher J.A., and Rubin B.P. KIT mutations in GIST. Curr Opin Genet Dev 17 (2007) 3-7
57. Sammarco I., Capurso G., Coppola L., et al. Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients. Int J Colorectal Dis 19 (2004) 545-553
58. Singer C.F., Hudelist G., Lamm W., Mueller R., Czerwenka K., and Kubista E. Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 11 (2004) 861-869
59. Koch C.A., Gimm O., Vortmeyer A.O., et al. Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy?. Ann N Y Acad Sci 1073 (2006) 517-526
60. Kostoula V., Khan K., Savage K., et al. Expression of c-kit (CD117) in neuroendocrine tumours-a target for therapy?. Oncol Rep 13 (2005) 643-647
61. Ferrari L., Della Torre S., Collini P., et al. Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. Tumori 92 (2006) 531-535
62. Chaudhry A., Funa K., and Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 32 (1993) 107-114
63. Funa K., Papanicolaou V., Juhlin C., et al. Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 50 (1990) 748-753
64. Capdeville R., Buchdunger E., Zimmermann J., and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1 (2002) 493-502
65. Lankat-Buttgereit B., Horsch D., Barth P., Arnold R., Blocker S., and Goke R. Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 71 (2005) 131-140
66. Yao J.C., Yeung S.J., Rashid A., et al. Early results of a phase II trial of imatinib in patients with advanced carcinoid tumor. Proc Am Soc Clin Oncol 22 (2003) 1491
67. Yao J.C., Zhang J.X., Rashid A., et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 13 (2007) 234-240
68. Gross D.J., Munter G., Bitan M., et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 13 (2006) 535-540
69. Averous J., and Proud C.G. When translation meets transformation: the mTOR story. Oncogene 25 (2006) 6423-6435
70. Easton J.B., and Houghton P.J. mTOR and cancer therapy. Oncogene 25 (2006) 6436-6446
71. Land S.C., and Tee A.R. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signalling motif. J Biol Chem 282 (2007) 20534-20543
72. Panwalkar A., Verstovsek S., and Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100 (2004) 657-666
73. Mita M.M., Mita A., and Rowinsky E.K. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 4 Suppl. 1 (2003) S169-S177
74. Francalanci P., Diomedi-Camassei F., Purificato C., et al. Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol 27 (2003) 1386-1389
75. Merritt II J.L., Davis D.M., Pittelkow M.R., and Babovic-Vuksanovic D. Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations. Am J Med Genet A 140 (2006) 1669-1672
76. Wang L., Ignat A., and Axiotis C.A. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 10 (2002) 139-146
77. Perren A., Komminoth P., Saremaslani P., et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 157 (2000) 1097-1103
78. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., and Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 102 (2005) 8573-8578
79. Blansfield J.A., Choyke L., Morita S.Y., et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 142 (2007) 814-818
80. Corcos O., Couvelard A., Giraud S., et al. Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features. Pancreas 37 (2008) 85-93
81. von Wichert G., Jehle P.M., Hoeflich A., et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 60 (2000) 4573-4581
82. Kidd M., Eick G.N., Modlin I.M., Pfragner R., Champaneria M.C., and Murren J. Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J Mol Endocrinol 38 (2007) 181-192
83. Charland S., Boucher M.J., Houde M., and Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein(MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 142 (2001) 121-128
84. Theodoropoulou M., Zhang J., Laupheimer S., et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 66 (2006) 1576-1582
85. Moreno A., Akcakanat A., Munsell M.F., Soni A., Yao J.C., and Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15 (2008) 257-266
86. Cloughesy T.F., Yoshimoto K., Nghiemphu P., et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5 (2008) e8
87. Duran I., Kortmansky J., Singh D., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95 (2006) 1148-1154
88. Zitzmann K., De Toni E.N., Brand S., et al. The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85 (2007) 54-60
89. Hörsch D., Tielke S., and Schrader J. Expression and activation of mTOR in neuroendocrine tumors. Effects of mTOR inhibition by RAD001 upon growth, cell cycle regulation and signalling in neuroendocrine cell lines. J Clin Oncol 25 18S (2007) 10570
90. Grozinsky-Glasberg S., Franchi G., Teng M., et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 87 (2008) 168-181
91. Yao J.C., Phan A., Chang D.Z., et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate grade neuroendocrine tumours: results of a phase II study. J Clin Oncol 26 (2008) 4311-4318
92. Yao J.C., Lombard-Bohas C., Baudin E., et al. A phase II trial of daily oral RAD001 (everolimus) in patients with metastatic pancreatic neuroendocrine tumors (NET) after failure of cytotoxic chemotherapy. Ann Oncol 19 Suppl. 8 (2008) 508PD viii167
93. Sung M.W., Kvols L., Wolin E., Jacob G., Talluto C., and Torres J.C. Phase II proof-of-concept study of atiprimod in patients with advanced low- to intermediate-grade neuroendocrine carcinoma. J Clin Oncol 26 Suppl. (2008) 4611
94. Mizuno S., Kato K., Hashimoto A., et al. Expression of cyclo-oxygenase-2 in gastrointestinal carcinoid tumors. J Gastroenterol Hepatol 21 (2006) 1313-1319
95. Okami J., Nakamori S., Yamamoto H., et al. An immunohistochemical study of cyclooxygenase (COX)-2 expression in endocrine tumors of the pancreas. J Exp Clin Cancer Res 21 (2002) 569-576
96. Ohike N., and Morohoshi T. Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation. Pathol Int 51 (2001) 770-777
97. Cadden I., Johnston B.T., Turner G., McCance D., Ardill J., and McGinty A. An evaluation of cyclooxygenase-2 as a prognostic biomarker in mid-gut carcinoid tumours. Neuroendocrinology 86 (2007) 104-111
98. Detjen K.M., Welzel M., Wiedenmann B., and Rosewicz S. Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer 107 (2003) 844-853
99. Krzyzanowska M.K., Tsao M.S., Oza A.M., et al. Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours. Clin Oncol (R Coll Radiol) 18 (2006) 88-89
100. Wulbrand U., Remmert G., Zofel P., Wied M., Arnold R., and Fehmann H.C. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur J Clin Invest 30 (2000) 729-739
101. Furukawa M., Raffeld M., Mateo C., et al. Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res 11 (2005) 3233-3242
102. Nilsson O., Wängberg B., Theodorsson E., Skottner A., and Ahlman H. Presence of IGF-I in human midgut carcinoid tumours-an autocrine regulator of carcinoid tumour growth?. Int J Cancer 51 (1992) 195-203
103. Lopez T., and Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1 (2002) 339-353
104. Easton B., Kurmasheva R.T., and Houghtom P.J. IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell 9 (2006) 153-155
105. Di Cosimo S., Seoane J., Guzman M., et al. Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: a mechanistic based anti-tumor strategy. J Clin Oncol 23 16S (2005) 3112
106. Playford M.P., and Schaller M.D. The interplay between Src and integrins in normal and tumor biology. Oncogene 23 (2004) 7928-7946
107. Di Florio A., Capurso G., Milione M., et al. Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. Endocr Relat Cancer 14 (2007) 111-124
108. Tabernero J., Cervantes A., Hoekman K., et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: first demonstration of inhibition of Src activity in human cancers. J Clin Oncol 25 18S (2007) 3520
109. Baradari V., Huether A., Hopfner M., Schuppan D., and Scherubl H. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 13 (2006) 1237-1250
110. Cecconi D., Donadelli M., Rinalducci S., et al. Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. Proteomics 7 (2007) 1644-1653
111. Zavrski I., Kleeberg L., and Kaiser M. Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des 13 (2007) 471-485
112. Shah M.H., Young D., and Kindler H.L. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10 (2004) 6111-6118
113. Gills J.J., Lopiccolo J., Tsurutani J., et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 13 (2007) 5183-5194
114. Brunner T.B., Geiger M., Grabenbauer G.G., et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 26 (2008) 2699-2706
115. Marion-Audibert A.M., Barel C., Gouysse G., et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125 (2003) 1094-1104
116. Arsham A.M., Howell J.J., and Simon M.C. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278 (2003) 29655-29660
117. Sullivan R., Paré G.C., Frederiksen L.J., Semenza G.L., and Graham C.H. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 7 (2008) 1961-1973
118. Wang X., Yue P., Kim Y.A., Fu H., Khuri F.R., and Sun S.Y. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 68 (2008) 7409-7418
119. Schnell C.R., Stauffer F., Allegrini P.R., et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 68 (2008) 6598-6607
120. Coulter D.W., Blatt J., D'Ercole A.J., and Moats-Staats B.M. IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. Anticancer Res 28 (2008) 1509-1516
121. Vojtechová M., Turecková J., Kucerová D., Sloncová E., Vachtenheim J., and Tuhácková Z. Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. Neoplasia 10 (2008) 99-107
122. Wang X., Yue P., Chan C.B., et al. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 27 (2007) 7405-7413
123. Phung T.L., Ziv K., Dabydeen D., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 (2006) 159-170
124. Fulton D., Gratton J.P., McCabe T.J., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 10 June (399) (1999) 597-601
125. Kaper F., Dornhoefer N., and Giaccia A.J. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res 66 (2006) 1561-1569
126. Huynh H., Chow P.K., Palanisamy N., et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 49 (2008) 52-60
127. http://www.clinicaltrial.gov. Identifier: NCT00569127.
128. Id: NCT00328497.
129. Id: NCT00609765.
130. Id: NCT00607113.
131. Id: NCT00428597.
132. Id: NCT00434109.
133. Id: NCT00131911.
134. Id: NCT00027638.
135. Id: NCT00075439.
136. Id: NCT00363051.
137. Id: NCT00412061.
138. Id: NCT00576680.
139. Id: NCT00655655.
140. Id: NCT00688623.
141. Id: NCT00610129.
142. Id: NCT00084461.
143. Id: NCT00436735.